Managing dyslipidemia in older adults

Journal of the American Geriatrics Society

Volumn 47, Issue 12, 1999, Pages 1458-1465

  Carlsson, Cynthia M ^a   Carnes, Molly ^a   McBride, Patrick E ^a   Stein, James H ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Aged; Cholesterol; Elderly; Heart disease; Hyperlipidemia

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; LOW DENSITY LIPOPROTEIN;

AGED; CORONARY RISK; DIET THERAPY; DYSLIPIDEMIA; HUMAN; ISCHEMIC HEART DISEASE; KINESIOTHERAPY; MEDICAL LITERATURE; PEER REVIEW; REVIEW; WEIGHT REDUCTION;

EID: 0032711899     PISSN: 00028614     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1532-5415.1999.tb01568.x     Document Type: Review

References (65)

1. Vital and Health Statistics. National Hospital Discharge Survey: Annual Summary, 1994. Series 13: Data from the National Health Care Survey No. 128. DHHS Publication No. (PHS) 97-1789. Washington, DC: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics.
2. Whitney FJ, Downs JR, Clearfield M et al. Air Force/Texas Coronary Atherosclerosis Prevention Study: Extending the benefit of primary prevention to healthy elderly men and women (abstract). Circulation 1998;98:I-46.
3. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
4. Los Angeles Veterans Administration Diet Study. Nutr Rev 1969;27:311-316.
5. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-1009.
6. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofihrate and nicotinic acid. Acta Med Scand 1988;223:405-418.
7. The Pravastatin Multinational Study Group for Cardiac Risk Patients. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. Am J Cardiol 1993;72:1031-1037.
8. Sempos CT, Cleeman JI, Carroll MD et al. Prevalence of high blood cholesterol among U.S. adults: An update based on guidelines from the Second Report of the National Cholesterol Education Program Adult Treatment Panel. JAMA 1993;269:3009-3014.
9. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993;269: 3015-3023.
10. Hazzard WR. Dyslipoproteinemia in the elderly: Should it be treated? Clin Geriatr Med 1992;8:89-102.
11. Newschaffer CJ, Bush TL, Hale WE. Aging and total cholesterol levels: Cohort, period, and survivorship effects. Am J Epidemiol 1992;136:23-34.
12. Kreisberg RA, Kasim S. Cholesterol metabolism and aging. Am J Med 1987;82(S1B):54-60.
13. Haffner SM, Miettinen H. Insulin resistance implications for type II diabetes mellitus and coronary heart disease. Am J Med 1997;103:152-162.
14. Reaven GM, Chen Y-D, Jeppesen J et al. Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. J Clin Invest 1993;92:141-146.
15. Harris T, Cook EF, Kannel WB, Goldman L. Proportional hazards analysis of risk factors for coronary heart disease in individuals aged 65 or older: The Framingham Heart Study. J Am Geriatr Soc 1988;36:1023-1028.
16. Corti MC, Guralnik JM, Salive ME et al. Clarifying the direct relation between total cholesterol levels and death from coronary heart disease in older persons. Ann Intern Med 1997;126:753-760.
17. Rubin SM, Sidney S, Black DM et al. High blood cholesterol in elderly men and the excess risk for coronary heart disease. Ann Intern Med 1990;113: 916-920.
18. Benfante R, Reed D. Is elevated serum cholesterol level a risk factor for coronary heart disease in the elderly? JAMA 1990;263:393-396.
19. Frost PH, Davis BR, Burlando AJ et al. Serum lipids and incidence of coronary heart disease: Findings from the Systolic Hypertension in the Elderly Program (SHEP). Circulation 1996;94:2381-2388.
20. Kronmal RA, Cain KC, Ye Z, Omenn GS. Total serum cholesterol levels and mortality risk as a function of age: A report based on the Framingham data. Arch Intern Med 1993;153:1065-1073.
21. Krumholz HM, Seeman TE, Merrill SS et al. Lack of association between cholesterol and coronary heart disease mortality and morbidity and all-cause mortality in persons older than 70 years. JAMA 1994;272:1335-1340.
22. Weverling-Rijinsburger AW, Blauw GJ, Lagaay AM et al. Total cholesterol and risk of mortality in the oldest old. Lancet 1997;350:1119-1123.
23. Reaven PD, McPhillips JB, Barrett-Connor EL, Criqui MH. Leisure time exercise and lipid and lipoprotein levels in an older population. J Am Geriatr Soc 1990;38:847-854.
24. Harris TB, Makuc DM, Kleinman JC et al. Is the serum cholesterol-coronary heart disease relationship modified by activity level in older persons? J Am Geriatr Soc 1991;39:747-754.
25. Seals DR, Hagberg JM, Hurley BF et al. Effects of endurance training on glucose tolerance and plasma lipid levels in older men and women. JAMA 1984;252:645-649.
26. Pescatello LS, DiPietro L. Physical activity in older adults: An overview of health benefits. Sports Med 1993;15:353-364.
27. Williams PT. Coronary heart disease risk factors of vigorously active sexagenarians and septuagenarians. J Am Geriatr Soc 1998;46:134-142.
28. Lavie CJ, Milani RV. Effects of cardiac rehabilitation programs on exercise capacity, coronary risk factors, behavioral characteristics, and quality of life in a large elderly cohort. Am J Cardiol 1995;76:177-179.
29. Lavie CJ, Milani RV. Effects of cardiac rehabilitation and exercise training programs in patients ≥ 75 years of age. Am J Cardiol 1996;78:675-677.
30. Lavie CJ, Milani RV. Benefits of cardiac rehabilitation and exercise training in elderly women. Am J Cardiol 1997;79:664-666.
31. Binder EF, Birge SJ, Kohrt WM. Effects of endurance exercise and hormone replacement therapy on serum lipids in older women. J Am Geriatr Soc 1996;44:231-236.
32. Motoyarna M, Sunami Y, Kinoshita F et al. The effects of long-term low intensity aerobic training and detraining on serum lipid and lipoprotein concentrations in elderly men and women. Eur J Appl Physiol 1995;70:126-131.
33. Katzel LI, Bleecker ER, Colman EG et al. Effects of weight loss vs aerobic exercise training on risk factors for coronary disease in healthy obese, middle-aged and older men: A randomized controlled trial. JAMA 1995; 274:1915-1921.
34. FonongT, Toth MJ, Ades PA et al. Relationship between physical activity and HDL-cholesterol in healthy older men and women: A cross-sectional and exercise intervention study. Atherosclerosis 1996;127:177-183.
35. Denke MA. Cholesterol-lowering diets: A review of the evidence. Arch Intern Med 1995;155:17-26.
36. Denke MA. Response to a cholesterol-lowering diet: Efficacy is greater in hypercholesterolemic subjects even after adjustment for regression to the mean. Am J Med 1993;94:626-631.
37. Schaefer EJ, Lichtenstein AH, Lamon-Fava S et al. Efficacy of a National Cholesterol Education Program Step 2 Diet in normolipidemic and hypercholesterolemic middle-aged and elderly men and women. Arterioscler Thromb Vasc Biol 1995;15:1079-1085.
38. Schaefer EJ, Lichtenstein AH, Lamon-Fava S et al. Effects of National Cholesterol Education Program Step 2 Diets relatively high or relatively low in fish-derived fatty acids on plasma lipoproteins in middle-aged and elderly subjects. Am J Clin Nutr 1996;63:234-241.
39. Geil PB, Anderson JW, Gustafson NJ. Women and men with hypercholesterolemia respond similarly to an American Heart Association Step 1 Diet. J Am Diet Assoc 1995;95:436-441.
40. Schaefer EJ, Lichtenstein AH, Lamon-Fava S et al. Body weight and low-density lipoprotein cholesterol changes after consumption of a low-fat ad libitum diet. JAMA 1995;274:1450-1455.
41. Denke MA. Individual responsiveness to a cholesterol-lowering diet in postmenopausal women with moderate hypercholesterolemia. Arch Intern Med 1994;154:1977-1982.
42. Jensen CD, Haskell W, Whittam JH. Long-term effects of water-soluble dietary fiber in the management of hypercholesterolemia in healthy men and women. Am J Cardiol 1997;79:34-37.
43. Chan EK, Schroeder DJ. Psyllium in hypercholesterolemia. Ann Pharmacother 1995;29:625-627.
44. Bell LP, Hectorne K, Reynolds H et al. Cholesterol-lowering effects of psyllium hydrophilic mucilloid. Adjunct therapy to a prudent diet for patients with mild to moderate hypercholesterolemia. JAMA 1989;261:3419-3423.
45. Davidson MH, Maki KC, Kong JC et al. Long-term effects of consuming foods containing psyllium seed husk on serum lipids in subjects with hypercholesterolemia. Am J Clin Nutr 1998;67:367-376.
46. Hunninghake DB, Miller VT, LaRosa JC et al. Hypocholesterolemic effects of a dietary fiber supplement. Am J Clin Nutr 1994;59:1050-1054.
47. de Lorgeril M, Salen P, Martin JL, et al. Effect of a Mediterranean type of diet on the rate of cardiovascular complications in patients with coronary artery disease: Insights into the cardioprotective effects of certain nutriments. J Am Coll Cardiol 1996;28:1103-1108.
48. de Lorgeril M, Salen P, Martin JL et al. Mediterranean diet, traditional risk factors and the rate of cardiovascular complications after myocardial infarction: Final report of the Lyon Diet Heart Study. Circulation 1999;99:779-785.
49. Santinga JT, Rosman HS, Rubenfire M et al. Efficacy and safety of pravastatin in the long-term treatment of elderly patients with hypercholesterolemia. Am J Med 1994;96:509-515.
50. Chan P, Lee C, Lin T et al. The effectiveness and safety of low dose pravastatin in elderly hypertensive hypercholesterolemic subjects on antihypertensive therapy. Am J Hypertens 1995;8:1099-1104.
51. LaRosa JC, Applegate W, Crouse JR et al. Cholesterol lowering in the elderly: Results of the Cholesterol Reduction in Seniors Program (CRISP) Pilot Study. Arch Intern Med 1994;154:529-539.
52. Miettinen TA, Pyörälä K, Olsson AG et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris; Findings from the Scandinavian Simvastatin Survival Study (4S). Circulation 1997;96:4211-4218.
53. Denke MA. Effects of continuous combined hormone-replacement therapy on lipid levels in hypercholesterolemic postmenopausal women. Am J Med 1995;99:29-35.
54. Darling GM, Johns JA, McCloud PI, Davis SR. Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women. N Engl J Med 1997;337:595-601.
55. Hulley S, Grady D, Bush T et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-613.
56. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995;273:199-208.
57. Belchetz PE. Hormonal treatment of postmenopausal women. N Engl J Med 1994;330:1062-1071.
58. Black DM, Bakker-Arkema RG, Nawrocki JW. An overview of the clinical safety profile of atorvastatin (Lipitor), a new HMG-CoA reductase inhibitor. Arch Intern Med 1998;158:577-584.
59. Santanello NC, Barber BL, Applegate WB et al. Effect of pharmacologic lipid lowering on health-related quality of life in older persons: Results from the Cholesterol Reduction in Seniors Program (CRISP) Pilot Study. J Am Geriatr Soc 1997;45:8-14.
60. Lewis SJ, Moye LA, Sacks FM et al. Effect of Pravastarin on Cardiovascular Events in Older Patients with Myocardial Infarction and Cholesterol Levels in the Average Range. Ann Intern Med 1998;129:681-689.
61. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol values. N Engl J Med 1998;339:1349-1357.
62. Rubins HB, Robins SJ, Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999;341:410-418.
63. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Group. N Engl J Med 1995;333:1301-1307.
64. Johannesson M, Jonsson B, Kjekshus J et al. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med 1997;336:332-336.
65. Hamilton VH, Racicot FE, Zowall H et al. The cost effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease: Estimating the benefits of increasing HDL-C. JAMA 1995;273:1032-1038.